In a report released yesterday, Steve Baxter from Wells Fargo maintained a Hold rating on Cencora (COR – Research Report), with a price ...

Analyst Charles Rhyee of TD Cowen maintained a Buy rating on Cencora (COR – Research Report), with a price target of $288.00. Charles ...

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches.

Cencora, Inc. is a pharmaceutical sourcing and ... The U.S. Healthcare Solutions segment focuses on the distribution of specialty, brand-name, and generic pharmaceuticals. The International ...

The likely GOP sweep of the House, Senate and White House has dampened expectations for health care policy riding in a lame-duck package.

Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 ...

Cencora, Inc. COR is well-poised for growth ... the introduction of innovative drugs like hepatitis C treatments and a strong brand pricing environment are expected to contribute positively.

Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in ...